Geisinger Health
Danville, Pennsylvania, 17822, United States
NCT Number: NCT06696066
The goal of this pilot study is to evaluate the feasibility and acceptability of implementing a peer recovery support program to support patient engagement in medication treatment for opioid use disorder (MOUD). The program, entitled "Promoting Enhanced Engagement through Recovery Support" (PEERS) was developed in collaboration with community and clinical partners for the MOUD outpatient setting. Information gathered during this pilot study will inform refinements to the program and study components for a future clinical trial that will evaluate the effectiveness of the peer recovery support program in increasing patient retention in MOUD.
The investigators will recruit 12 participants to the pilot study, all of whom will receive the PEERS program. The study will take place in Geisinger outpatient addiction treatment clinics in northeast Pennsylvania. Patients initiating MOUD treatment at one of the clinics will be eligible for participation, and will be recruited via email, patient portal messages, and phone. Each participant will receive the PEERS program, entailing regular sessions with a Certified Recovery Specialist (CRS) for 6 months. Participants will also be asked to complete assessments at baseline and 12 weeks and will be invited to provide qualitative feedback on their experience with the program through an interview conducted between 8-12 weeks. As the focus of the pilot pertains to the feasibility and acceptability of the program and the study components, study outcomes focus on participant engagement in and acceptance of the program, CRS fidelity to the program, barriers to implementation, and feasibility of data collection.
Looking for future studies?
Notify Me18 year–89 year
All sexes
Interventional
Not applicable
Danville, Pennsylvania, 17822, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Peer Recovery Support program will be delivered by a certified recovery specialist (CRS) over the course of 6-months. The CRS will provide supportive care to the participant during their initial 6-months of MOUD treatment to increase patient engagement in their treatment. The CRS may provide emotional support; help participants to identify their recovery assets, goals, and barriers; guide participants in creating a recovery plan; help participants to increase their coping skills; and assist participants in connecting to community and recovery resources.
Time frame: Baseline to 12 weeks
Percent of participants who attended at least 2 sessions with the Certified Recovery Specialist
Time frame: 12 weeks
Participants' average scores for the Scales for Participant Alliance with Recovery Coach (SPARC-2); score can range from 1-5 and a high score indicates greater satisfaction with the CRS.
Time frame: Baseline
Percent of participants who completed the baseline assessment
Time frame: 12 weeks
Percent of participants who completed the follow-up assessment
Geisinger Clinic
Other
Pilot Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Disorder Treatment
Acronym: PEERS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07549126
Chemically-Induced Disorders, Clinical Decision Support
Guilford, Connecticut, United States
View Trial DetailsNCT05109429
Chemically-Induced Disorders, Measure Development
Baltimore, Maryland, United States
View Trial DetailsNCT05459922
Chemically-Induced Disorders, Mental Disorders
Phoenix, Arizona, United States
View Trial DetailsNCT05853289
Chemically-Induced Disorders, Mental Disorders
Baltimore, Maryland, United States
View Trial Details